The $200M Bet That You've Been Taking Your Lung Drugs Wrong

AP02 takes the same approach with nintedanib, the other major oral antifibrotic. Preclinical data showed it could match the lung concentrations of oral dosing while delivering lower overall body exposure. The Phase 2 AURA trial dosed its first patient in March 2026, and the money from this offering will push AP02 toward its own Phase 3.

Then there's AP03, a combination of both drugs in a single inhaled dose. It's still preclinical, but the logic is compelling: if each drug works better when inhaled alone, combining them could offer the best of both worlds with a fraction of the side effects patients experience when taking two oral pills. Phase 1 is on the roadmap.

Avalyn Didn't Just Appear Out of Thin Air

Originally called Genoa Pharmaceuticals, the company has been quietly building since 2011. CEO Lyn Baranowski joined in October 2022, bringing a résumé that reads like a highlight reel of respiratory biotech exits.

Before this IPO, Avalyn raised over $310 million from private investors, including a $100 million Series D in July 2025 backed by Novo Holdings, Suvretta Capital, and SR One. The company entered 2026 with $138 million in cash on hand. Combined with IPO proceeds, that's a serious war chest.

The Bigger Picture: Biotech IPOs Are Back

Avalyn's offering isn't happening in a vacuum. After a dismal 2025, 2026 has roared back. By mid-April, eight biotech companies had already gone public, raising a combined $2.47 billion. Aktis Oncology pulled in $318 million in January. Generate:Biomedicines raised $400 million in February. Analysts are now projecting 30 to 35 biotech IPOs for the full year.

The common thread? Investors want clinical-stage companies with de-risked assets and clear paths to pivotal data. Speculative, preclinical-stage stories are still struggling. But companies like Avalyn, which are reformulating proven drugs and heading into late-stage trials, fit the current appetite perfectly.

Truist Securities' Michael Allwin expressed hope that 2026 activity would normalize to levels resembling 2019 rather than the frothy peaks of 2020 and 2021. So far, the trajectory looks healthy.

A Competitive Landscape That's Surprisingly Thin

You might expect the inhaled pulmonary fibrosis space to be crowded. It isn't. The most notable inhaled competitor is Rein Therapeutics' LTI-03, a caveolin-1 peptide in Phase 2 for IPF with interim data expected in late 2026. United Therapeutics' inhaled treprostinil (Tyvaso) hit its Phase 3 endpoint in IPF in its TETON-1 trial in March 2026, but that drug targets a different mechanism.

The biggest recent approval in the space was Boehringer Ingelheim's nerandomilast (brand name Jascayd), an oral PDE4 inhibitor that became the first new IPF therapy in over a decade when it won FDA approval in 2025. But it's still a pill, which means it still comes with the systemic exposure problem Avalyn is trying to solve.

No one else is running late-stage trials with inhaled versions of pirfenidone or nintedanib. If Avalyn's approach works in Phase 3, they'd essentially own a category.

The Bottom Line

Avalyn's bet is that the best new lung drugs might be the old lung drugs, just delivered smarter. It's not the flashiest pitch in biotech; there's no gene therapy, no AI-designed molecule, no platform with twelve indications. It's a company saying: "These drugs already work. Patients just can't tolerate them. Let us fix that."

With over $200 million in fresh capital and a competitive landscape with remarkably little traffic, Avalyn has a real shot at building something significant. The risk, of course, is that Phase 3 trials are unforgiving. Plenty of good Phase 2 data has evaporated in pivotal studies.

But if you're going to bet on a reformulation story, betting on one where patients are literally quitting their medication because of side effects is a pretty good place to start.